You've made a very astute observation. The stock wouldn't go to $1,000/share without splitting. Today's market cap of about $8B would / could / should rise to a market cap of $118B.
I believe a stock should split 2-1 whenever it is sustained above $100/share. So that means we need to talk market cap, not share price. In short, we could see the value increase more than 14x in the next 5-years. So an investment of $10,000 would rise to $140,000 and an investment of $100,000 would rise to $1,400,000.
A nice return no matter how you look at it.
Looking at the pipeline that ISIS has, calculating the potential market value of each drug (with normal market penetration, not unseating a dominant market player, but what can be expected), factored by the probability of approval (different for each drug, none higher than 70% probability, some as low as 10%), I come out with a potential value for ISIS in excess of $1000/share. Now it will take 5 years + to get there, but this is why people are scooping up shares. Because it has that kind of a payback potential.
They do have to navigate through the regulatory maze, but everyone is lining up for ISIS. Their pipeline is the richest we've ever seen for any company in history. This is a break the bank kind of stock. Be patient, ignore the momentary spikes up and down, and we all will be richly rewarded.
ISIS has one of the deepest/best pipelines of drugs of any biopharmaceutical. Be glad they don't have any drugs approved and on the street yet or you'd be paying $500/share for this stock.
Hitting on all cylinders.
The management team should do the right thing and resign. That is in the best interests of all involved. This way the FDA can point to that old management team as the problem, which would clear the way to approve eteplirsen and get the NDA filed. Shareholders would be satisfied as they have given this management team far more than enough chances to get the NDA filed, and these guys haven't been able to get it done. Parents will be satisfied that finally action is being taken that will help their kids get the medication they need.
The Bollinger bands on SRPT are converging to a very tight range indicating a breakout is imminent either up or down. When looking at the MACD & Stochastics it becomes clear a major swelling is happening forming a solid foundation at $20-$21 price range with increasing pressure to the upside. This tells us this stock is poised for a major upward move (25%+) in the next 3-months.
Hopefully not until it goes to $50 then hey can buyout at $100/share.
They simply cannot afford not to. Right now they can take a stake for pennies on the dollar. Watch for several big pharmas (multiple) to take a minority stake in both SRPT and TKMR.
Final quarter. AA is coming. Will it be in October, November, or December?
Can you afford to wait and risk missing out on a double before year end?